PERRIGO Co plc (PRGO) stock
PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3028% below fair value
$16.04−0.90 (-5.31%)
Close on Nov 19, 2026Market cap $2.23BP/E –Yield 7.23%
Perrigo gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Perrigo's gross profit for the twelve months ending Jun 27, 2026 was $1.38B, down 10.8% year over year. For fiscal 2025 it was $1.49B, down 3.1% from the year before. Over ten years it grew 0.3% a year on average. The highest annual figure on record is $1.98B in fiscal 2017.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.49B | -3.1% |
| FY2024 | Dec 31, 2024 | $1.54B | -8.2% |
| FY2023 | Dec 31, 2023 | $1.68B | +15.5% |
| FY2022 | Dec 31, 2022 | $1.46B | +2.8% |
| FY2021 | Dec 31, 2021 | $1.42B | -5.3% |
| FY2020 | Dec 31, 2020 | $1.49B | +4.3% |
| FY2019 | Dec 31, 2019 | $1.43B | -21.7% |
| FY2018 | Dec 31, 2018 | $1.83B | -7.5% |
| FY2017 | Dec 31, 2017 | $1.98B | +20.4% |
| FY2015 | Jun 27, 2015 | $1.64B | +13.2% |
| FY2014 | Jun 28, 2014 | $1.45B | +13.4% |
| FY2013 | Jun 29, 2013 | $1.28B | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 27, 2026 | $313.90M | -13.5% |
| Q1 FY2026CQ1 2026 | Mar 28, 2026 | $325.50M | -17.0% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $362.20M | -6.1% |
| Q3 FY2025CQ3 2025 | Sep 27, 2025 | $377.10M | -6.8% |
| Q2 FY2025CQ2 2025 | Jun 28, 2025 | $362.90M | -8.1% |
| Q1 FY2025CQ1 2025 | Mar 29, 2025 | $392.30M | +9.7% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $385.90M | -9.7% |
| Q3 FY2024CQ3 2024 | Sep 28, 2024 | $404.40M | -1.7% |
| Q2 FY2024CQ2 2024 | Jun 29, 2024 | $394.70M | -7.8% |
| Q1 FY2024CQ1 2024 | Mar 30, 2024 | $357.70M | -13.6% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $427.30M | +11.7% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $411.20M | +13.3% |
| Q2 FY2023CQ2 2023 | Jul 1, 2023 | $428.00M | +15.0% |
| Q1 FY2023CQ1 2023 | Apr 1, 2023 | $413.80M | +22.5% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $382.60M | +5.6% |
| Q3 FY2022CQ3 2022 | Oct 1, 2022 | $362.90M | +7.9% |
| Q2 FY2022CQ2 2022 | Jul 2, 2022 | $372.10M | +6.6% |
| Q1 FY2022CQ1 2022 | Apr 2, 2022 | $337.80M | -8.3% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $362.40M | -22.8% |
| Q3 FY2021CQ3 2021 | Oct 2, 2021 | $336.40M | -9.0% |
| Q2 FY2021CQ2 2021 | Jul 3, 2021 | $349.00M | +0.5% |
| Q1 FY2021CQ1 2021 | Apr 3, 2021 | $368.40M | -6.4% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $469.20M | -2.4% |
| Q3 FY2020CQ3 2020 | Sep 26, 2020 | $369.70M | -10.4% |
| Q2 FY2020CQ2 2020 | Jun 27, 2020 | $347.20M | -19.4% |
| Q1 FY2020CQ1 2020 | Mar 28, 2020 | $393.70M | -12.3% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $480.90M | +8.6% |
| Q3 FY2019CQ3 2019 | Sep 28, 2019 | $412.80M | -2.8% |
| Q2 FY2019CQ2 2019 | Jun 29, 2019 | $430.80M | -8.5% |
| Q1 FY2019CQ1 2019 | Mar 30, 2019 | $448.80M | -8.9% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $443.00M | -13.6% |
| Q3 FY2018CQ3 2018 | Sep 29, 2018 | $424.80M | -14.7% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $471.00M | -6.7% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $492.70M | +6.1% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $512.70M | -14.7% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $497.80M | +34.8% |
| Q2 FY2017CQ2 2017 | Jul 1, 2017 | $504.60M | – |
| Q1 FY2017CQ1 2017 | Apr 1, 2017 | $464.40M | – |
| Q4 FY2015CQ2 2015 | Jun 27, 2015 | $601.00M | – |
| Q3 FY2015CQ1 2015 | Mar 28, 2015 | $369.40M | – |
See a number that looks wrong?